^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CYP11A1 inhibitor

24d
Trial completion
|
prednisone • itraconazole • opevesostat (MK-5684)
1m
Safety and pharmacokinetics of odm-208 in patients with metastatic castration-resistant prostate cancer (2024-517439-39-00)
P1/2, N=129, Completed, Orion Corporation | Active, not recruiting --> Completed
Trial completion
|
opevesostat (MK-5684) • midazolam hydrochloride
2ms
Trial primary completion date
2ms
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
prednisone • itraconazole • opevesostat (MK-5684)
3ms
OMAHA-003: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2028 --> Feb 2030
Trial completion date
|
enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
3ms
Enrollment open
|
prednisone • itraconazole • opevesostat (MK-5684)
3ms
Trial completion
|
opevesostat (MK-5684)
3ms
New P1 trial
|
prednisone • itraconazole • opevesostat (MK-5684)
3ms
Trial initiation date • Pan tumor
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • EGFR positive
|
tamoxifen • fulvestrant • letrozole • exemestane • megestrol • opevesostat (MK-5684)
4ms
Enrollment closed
|
enzalutamide • abiraterone acetate • prednisone • opevesostat (MK-5684)
4ms
Trial completion
|
opevesostat (MK-5684)
5ms
Trial completion
|
prednisone • opevesostat (MK-5684)